Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | PLA2G4B | P0C869 | 7/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | RARB | P10826 | 4/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3857282 | 0.84 | ALOX5 (0.51) | ALDH1A1 | |
| SCHEMBL3703542 | 0.76 | BCL9 (0.61) | ALDH1A1KMT2A | |
| SCHEMBL265614 | 0.74 | TP53 (0.70) | TP53CA1CA2ALDH1A1 | |
| SCHEMBL10792394 | 0.74 | ALDH1A1 (0.47) | TP53TSHRRARBALDH1A1KMT2A | |
| SCHEMBL6562062 | 0.74 | BCL9 (0.58) | TP53TSHRPLA2G4BCA1CA2 | |
| SCHEMBL28444066 | 0.73 | KDM4E (0.55) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6563873 | 0.72 | BCL9 (0.57) | TP53TSHRPLA2G4BCA1CA2 | |
| SCHEMBL20273171 | 0.72 | CA1 (0.59) | TP53TSHRPLA2G4BCA1CA2 | |
| Terephthalic Acid SCHEMBL9943962 | 0.72 | FFAR3 (0.62) | TP53TSHRPLA2G4BCA1CA2 | |
| SCHEMBL9787297 | 0.71 | CYP3A4 (0.64) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054629-A1 | Inhibitors of Transthyretin Amyloid Fibril Formation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-02-26 | — | — | US | disclosed |
| US-7312361-B2 | Inhibitors of transthyretin amyloid fibril formation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-12-25 | — | — | US | disclosed |
| US-20060178527-A1 | Inhibitors of transthyretin amyloid fibril formation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054629-A1 | Inhibitors of Transthyretin Amyloid Fibril Formation | TTR, TTPA, APOB | TP53 895/4885TSHR 1585/4885PLA2G4B 3375/4885 |
| US-20060178527-A1 | Inhibitors of transthyretin amyloid fibril formation | TTR, TTPA, APOB | TP53 895/4885TSHR 1585/4885PLA2G4B 3375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.